Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jan 22;52(2):225-33.
doi: 10.1021/jm800498e.

Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins

Adam J T Smith  1 , Xiyun Zhang, Andrew G Leach, K N Houk
Affiliations

Beyond picomolar affinities: quantitative aspects of noncovalent and covalent binding of drugs to proteins

Adam J T Smith et al. J Med Chem. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Summary of the typical binding constants for host–guest complexes. For each class, the binding distribution is represented by an idealized normal distribution. Each curve is normalized to have the same area, the maximum occurs at the average value of Ka, and the standard deviation is used to set the width of the curve. Reprinted with permission from reference . Copyright 2005 Americal Chemical Society.
Figure 2
Figure 2
Plot of log Ka versus buried solvent accessible surface area (ΔSASA). Reprinted with permission from reference . Copyright 2005 Americal Chemical Society.
Figure 3
Figure 3
Frequency plot of association constant for 507 antibody–antigen complexes, 160 enzyme–inhibitor complexes, and 1017 measurements of enzyme–transition state complex. Reprinted with permission from reference . Copyright 2005 Americal Chemical Society.
See this image and copyright information in PMC

References

    1. Pauling L. The Nature of Forces Between Large Molecules of Biological Interest. Nature. 1948;161:707–709. - PubMed
    1. Congreve M, Murray CW, Blundell TL. Structural Biology and Drug Discovery. Drug Discov Today. 2005;10(13):895–907. - PubMed
    1. Williams SP, Kuyper LF, Pearce KH. Recent Applications of Protein Crystallography and Structure-Guided Drug Design. Curr Opin Chem Biol. 2005;9(4):371–380. - PubMed
    1. Gill AL, Frederickson M, Cleasby A, Woodhead SJ, Carr MG, Woodhead AJ, Walker MT, Congreve MS, Devine LA, Tisi D, O’Reilly M, Seavers LC, Davis DJ, Curry J, Anthony R, Padova A, Murray CW, Carr RA, Jhoti H. Identification of Novel p38alpha MAP Kinase Inhibitors Using Fragment-Based Lead Generation. J Med Chem. 2005;48(2):414–426. - PubMed
    1. Kaldor SW, Kalish VJ, Davies JF, 2nd, Shetty BV, Fritz JE, Appelt K, Burgess JA, Campanale KM, Chirgadze NY, Clawson DK, Dressman BA, Hatch SD, Khalil DA, Kosa MB, Lubbehusen PP, Muesing MA, Patick AK, Reich SH, Su KS, Tatlock JH. Viracept (Nelfinavir Mesylate, AG1343): a Potent, Orally Bioavailable Inhibitor of HIV-1 Protease. J Med Chem. 1997;40(24):3979–3985. - PubMed

Publication types